Abstract:Certain microRNAs (miRNAs/miRs) may be used as prognostic biomarkers in various types of cancer. The purpose of the present study was to identify miRNAs that were abnormally expressed in glioma of different grades, and to evaluate their clinical implications in patients with glioma. The differentially expressed miRNAs were evaluated from the expression profiles of six glioma tissues (three low-grade and three high-grade gliomas) determined using a microarray platform. Reverse transcription-quantitative polymerase chain reaction analysis was used to further verify the aberrant expression of the candidate miRNA in a set of 42 patients and 5 healthy controls. The miRNA target genes were predicted and the protein-protein interaction network was generated; furthermore, functional enrichment analysis of the target genes in Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was performed. Kaplan-Meier curves and Log-rank analysis, as well as multivariate Cox regression analysis were performed to assess the association of the candidate miRNA with patient survival. A total of 15 differentially expressed miRNAs, including 13 downregulated and 2 upregulated miRNAs, were identified by comparison of low-grade and high-grade glioma tissues. The miR-374a expression of high-grade gliomas was significantly lower than that of low-grade gliomas (fold change, -4.43; P=0.027). The expression levels of miR-374a gradually decreased with the increase of the pathological grade of glioma. Pearson's Chi-square test was used to determine the association of miR-374a expression with several clinicopathological factors. Furthermore, low expression of miR-374a was determined to be an independent prognostic marker and that it was significantly associated with overall survival (P=0.0213). GO and KEGG pathway analysis revealed that the target genes of miR-374a may be involved in the regulation of the RNA polymerase II promoter and mTOR signaling pathway. The four hub genes (CCND1, SP1, CDK4, CDK6) were also identified by PPI network analysis. In conclusion, the present study indicated that miR-374a may be used as a promising prognostic biomarker for the screening of high-risk populations and for the assessment of the prognosis of patients with glioma.

MicroRNA-133b expression associates with clinicopathological features and prognosis in glioma.

Prognostic role of microRNA-155 expression in gliomas: A meta-analysis

Decreased Expression of Microrna-107 Predicts Poorer Prognosis in Glioma

Expression and significance of miR-654-5p and miR-376b-3p in patients with colon cancer

Correlation of microRNA-10b upregulation and poor prognosis in human gliomas

Reduced Expression of Mir-3653 in Glioma and Its Correlations with Clinical Progression and Patient Survival

Identification of Differentially Expressed Micrornas and the Potential of Microrna-455-3p As a Novel Prognostic Biomarker in Glioma

Upregulation of Mir-183 Expression and Its Clinical Significance in Human Brain Glioma

Downregulation of Mir-154 in Human Glioma and Its Clinicopathological and Prognostic Significance

Mir-182 As a Prognostic Marker for Glioma Progression and Patient Survival

MicroRNA Signatures Predict Prognosis of Patients with Glioblastoma Multiforme Through the Cancer Genome Atlas.

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

Upregulation of microRNA‐133a and downregulation of connective tissue growth factor suppress cell proliferation, migration, and invasion in human glioma through the JAK/STAT signaling pathway

Downregulation of Microrna-374A Predicts Poor Prognosis in Human Glioma

Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patients.

Upregulation Of Mir-196b Confers A Poor Prognosis In Glioblastoma Patients Via Inducing A Proliferative Phenotype

Decreased Expression of Mir-378 Correlates with Tumor Invasiveness and Poor Prognosis of Patients with Glioma.

The Deregulation of Mir-133B is Associated with Poor Prognosis in Bladder Cancer.

Prognostic Value of Decreased Microrna-133A in Solid Cancers: a Meta-Analysis.

Clinical Significance of Microrna-145 Expression in Glioma